|Chemical and physical data|
|Molar mass||477.528 g·mol−1|
|3D model (JSmol)|
NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal models it has anxiolytic, antidepressant, and anorectic effects, and it has successfully passed Phase I clinical trials in humans.
The structure of NGD-4715 has been confused. For example, as 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine.
- Tarrant, J.; Hodgetts, K.J.; Chenard, B.L.; Krause, J.E.; Doller, D. (2017). "The Discovery of the MCH-1 Receptor Antagonist NGD-4715 for the Potential Treatment of Obesity". Comprehensive Medicinal Chemistry III. pp. 488–515. doi:10.1016/B978-0-12-409547-2.13785-0. ISBN 9780128032015.
- Chaki S, Kanuma K. (2007). "Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders". Drugs of the Future. 32 (9): 809. doi:10.1358/dof.2007.032.09.1131450.
- Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity. Business Wire. May 2 2007
- Neurogen acquired by Ligand Pharmaceuticals. Business Wire. August 24, 2009.
- Neurogen to sell Real Estate for $3.5m. Chicago Tribune. Nov 10, 2009
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|